This merger brings together scientific and operational excellence to support both established and early-stage therapeutic and medical device development. The integration is especially significant at a time when regulatory complexity, the potential for AI-driven innovation, and rising development costs require sophisticated and adaptable partners. The newly combined entity, LBRIA, underscores our shared commitment to applying best practices and advancing new technologies in today’s rapidly evolving landscape.

LBRIA builds on more than two decades of successful collaboration between the two organizations. The merger creates a full-service life sciences CRO with deep expertise in regulatory affairs, clinical design and management for Phase I–III trials, data collection and analysis, medical writing, and quality assurance—providing all the critical capabilities needed for successful product registration.

The combined strength of LBR and IA, now operating as LBRIA, delivers end-to-end clinical research services, expanded capacity, greater versatility, and robust scientific leadership tailored to pharmaceutical, biotechnology, and medical device companies. While maintaining the personalized service our clients value, LBRIA brings particular depth in key clinical areas, including anti-infectives, cannabis withdrawal, endocrine disorders, neurology, oncology, surgical interventions, and orphan drug and rare diseases.